Latest news for Oliveda Intl (OTC:OLVI) Stock

Oliveda International Inc is engaged in the manufacturing and distribution of cosmetic and holistic products built around the pure essence of the olive tree and oil. Its product lines include facial washes, serums, eye care products, and facial oils. Its body line of products includes washes, body oils, hand, and foot care products along with other bathing products. Its holistic products include products based upon the wholesome essence of extra virgin olive oil, with mouth drawing oils, Orac and Camu Camu concentrate, Hydroxytyrosol Molecule, Tea Olive Matcha, and other products that have been shown to help the body perform more efficiently, and hair products include both shampoo and conditioners which are foremost in the industry.

Penny Stocks

Tech

Media

INUV

MOBQ

SURG

OLVI

CMGO

MMND

ADTM

Mobiquity Technologies, Inc. (NASDAQ: MOBQ) announced that it has appointed Don Walker “Trey” Barrett, III to the role of Chief Operations and Strategy Officer, effective January 4, 2022.

Former Inuvo COO Joins Mobiquity Technologies as Chief Operations and Strategy Officer to Spearhead Next Phase of Growth

OLIVEDA INTERNATIONAL INC by Oliveda International, Inc.

Oliveda International Inc

Olvi Oyj

News

Guidance

VERV

Verve Therapeutics Says Well-capitalized With Cash Runway Extending Into Mid-2027

B of A Securities analyst Allen Lutz maintains Walgreens Boots Alliance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBA#NASDAQ">WBA</a>) with a Underperform and raises the price target from $7.5 to $8.5.

Price Target

Analyst Ratings

B of A Securities Maintains Underperform on Walgreens Boots Alliance, Raises Price Target to $8.5

HC Wainwright &amp; Co. analyst Edward White maintains Inozyme Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INZY#NASDAQ">INZY</a>) with a Buy and raises the price target from $14 to $16.

INZY

HC Wainwright & Co. Maintains Buy on Inozyme Pharma, Raises Price Target to $16

RNAC

Cartesian Therapeutics Expects Cash Resources  To Support Planned Operations, Including Completion Of Planned Phase 3 Trial For Descartes-08 For Myasthenia Gravis, Into Mid-2027

SLRX

Trading Halt: Halted at 7:55:00 a.m. ET - Trading Halt: Halt News Pending

B of A Securities analyst Doug Leggate upgrades Range Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RRC#NYSE">RRC</a>) from Neutral to Buy and raises the price target from $34 to $45.

Upgrades

B of A Securities Upgrades Range Resources to Buy, Raises Price Target to $45

Phio Pharmaceuticals Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHIO#NASDAQ">PHIO</a>) is a clinical-stage biotechnology company developing therapeutics that use its INTASYL&#xAE; siRNA gene silencing technology designed to make the body's immune cells more effective in killing cancer cells. Phio today announced pathologic responses for patients enrolled in the 2nd cohort, which includes 2 patients with a complete response or 100% tumor clearance.
Phio's ongoing Phase 1b clinical study (NCT 06014086) is designed to evaluate the safety and tolerability of neoadjuvant use of intratumoral PH-762 in Stages 1, 2 and 4 cutaneous squamous cell carcinoma, Stage 4 melanoma and Stage 4 Merkel cell carcinoma.
Of the patients enrolled to date, 6 patients were diagnosed with cutaneous squamous cell carcinoma and 1 patient was diagnosed with metastatic melanoma. At Day 36 (tumor excision), while patients in the first cohort had stable disease, results are now available for the 4 patients who completed treatment in the 2nd cohort:
<ul>
<li>Complete response (100% tumor clearance) is reported for 2 patients with cutaneous squamous cell carcinoma. Partial response (90% tumor clearance) is reported for 1 patient with cutaneous squamous cell carcinoma and 1 patient had stable disease, having not progressed.</li>
</ul>

PHIO

Phio Pharmaceuticals Reports 100% Tumor Clearance in Two Patients Using PH-762 in Phase 1b Cancer Study

SHAK

Shake Shack Expects To Grow FY25 Total Revenue By 16% - 18%, Continue To Expand Restaurant Margins To Approximately 22% And Grow Adjusted EBITDA By 14% - 20%

HC Wainwright &amp; Co. analyst Patrick Trucchio reiterates GH Research (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GHRS#NASDAQ">GHRS</a>) with a Buy and maintains $40 price target.

Reiteration

GHRS

HC Wainwright & Co. Reiterates Buy on GH Research, Maintains $40 Price Target

B of A Securities analyst Doug Leggate upgrades Gulfport Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPOR#NYSE">GPOR</a>) from Neutral to Buy and raises the price target from $164 to $227.

GPOR

B of A Securities Upgrades Gulfport Energy to Buy, Raises Price Target to $227

The company also provided an updated outlook on its long-term targets, including now seeing the potential for its Company-operated footprint to reach at least 1,500 Shacks over time, versus the prior target of 450 that was provided in conjunction with the Company's February 2015 initial public offering.
&nbsp;

Shake Shack Says Preliminary Unaudited Results Show That In Q4, It Grew Same-shack Sales By 4.3%, Total Revenue By 14.8%

Cryptocurrency experts are largely united in their belief that Bitcoin&#8216;s (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) <a href="https://www.benzinga.com/markets/cryptocurrency/25/01/42908193/exclusive-answering-key-questions-about-bitcoins-future-before-inauguration">long-term bull run remains intact</a>, even as the apex crypto struggles to keep <a href="https://www.benzinga.com/markets/cryptocurrency/25/01/42940555/bitcoin-slides-to-91000-ahead-of-upcoming-key-inflation-data">short-term bearish fears</a> away.
<h2 class="wp-block-heading">Hawkish Fed Threw A Wrench In Bitcoin&#8217;s Works</h2>
The recent market downturn, according to Bitfinex analysts, is primarily a result of &#8220;the Fed reducing the number of cuts in 2025 to two, signaling that it was taking a highly hawkish stance.&#8221; 
They further noted that it suggests a shift in market dynamics that might not be completely priced in, especially given that the FOMC minutes were released, but the market continues to sell off.
Marcin Kazmierczak, co-founder &amp; COO of Redstone, suggests that while macro conditions are a factor, &#8220;It's important to remember that the past year has been wild for the industry—BTC is up nearly 100% YoY—and we haven't seen a significant market downturn in quite a while. Naturally, some market participants are taking profits.&#8221;
He also points towards tax season contributing to the sell-offs. 
However, Marcin added that structurally, nothing major has changed, and crypto as an asset class still has plenty of tailwinds heading into 2025.
Tom Trowbridge, co-Founder of Fluence, sees the current dip &#8220;driven by the Fed&#8217;s hawkish stance and possibly a misunderstanding of the DOJ's Bitcoin sales news.&#8221; 
Still, &#8220;any short-term moves we're seeing now will ultimately be irrelevant as other nations follow the U.S.&#8217;s lead, causing Bitcoin's price to surge,&#8221; Trowbridge emphasizes.
Illia Otychenko, Lead Analyst at CEX.IO, frames the dip within Bitcoin's historical cycles, stating, &#8220;Historically, double-digit dips have been a hallmark of post-halving bull runs&#8230; Without these types of corrections, the rally&#8217;s long-term stability would raise even greater concerns.&#8221; 
He also highlighted that market had no clear catalyst for a correction — until the Federal Reserve's dot plot revealed updated rate cut projections for 2025.
This revelation fueled bearish sentiment and caused a pullback that was so needed for the market.
Adding a different perspective, James Davies, CEO of Crypto Valley Exchange, suggests the dip isn't US-isolated, saying &#8220;it&#8217;s not the FED, crypto is global, however it is likely related to the risk off approach everyone is taking as power changes hand in the US.&#8221; 
Georgii Verbitskii , founder of crypto investor app TYMIO, sums up the current state as caused by &#8220;a decrease in USD liquidity, release of negative macroeconomic data, and DOJ's permission to sell bitcoins&#8221; while adding, &#8220;At the same time, nothing changes in the long-term positive perspective&#8221;.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/01/42909925/previewing-todays-most-important-jobs-report-what-it-means-for-bitcoin">Previewing Today&#8217;s &#8216;Most Important Jobs Report&#8217; — What It Means For Bitcoin</a>
<h2 class="wp-block-heading">Inauguration More Likely To Be Bullish, Analysts Say</h2>
As <a href="https://www.benzinga.com/markets/equities/25/01/42938119/lockheed-martin-donates-1m-to-trumps-inaugural-committee-as-speculation-grows-over-elon-musk-led-doge-crackdown-on-traditional-defense-contracts">the inauguration</a> of President-elect Donald Trump approaches, market sentiment remains divided.
Bitfinex analysts anticipate &#8220;increased volatility&#8221; and said &#8220;The long term value proposition of a pro-Bitcoin stance remains incredibly bullish, more so for altcoins than Bitcoin currently.&#8221; 
Kazmierczak believes volatility is inevitable, as Trump's inauguration has been a known market event since election day and is likely already priced in.
Trowbridge believes that the first few weeks after the inauguration are likely to bring some positive announcements for crypto. 
Otychenko suggests the inauguration &#8220;looks like a priced-in event&#8221; adding &#8220;This difference between expectations and actual actions may lead to some investor disappointment, temporarily limiting upward momentum.&#8221;
Davies stated, &#8220;Normally we buy the rumour and sell the event. De-Risking is so people can react quickly&#8221;. 
&#8220;The ascendance of Trump will bring more positive news for crypto,&#8221; Verbitskii said, adding that his team has been developing plans all this time, and the crypto market will like details as soon as they start announcing them.
<h2 class="wp-block-heading">Has Bitcoin Topped For This Cycle</h2>
Bitfinex analysts believe it is unlikely that the market has topped and that it was an intermediate top, and will be followed by a lengthy pullback.
Kazmierczak puts the probability at 20% and believes crypto as an asset class is structurally strong for the year ahead.
Trowbridge said, &#8220;No, I don&#8217;t think $108,000 was the top either&#8221; and believes &#8220;the longer-term bull case for Bitcoin seems solid&#8221;. Otychenko places the probability at &#8220;less than 5%&#8221; stating that it would suggest a capitulation of Bitcoin&#8217;s &#8220;store of value / hedging camp, which seems unlikely&#8221; with 64% of Bitcoin supply remains in the hands of long-term holders.
Davies believes &#8220;the market doesn&#8217;t think $108,000 was the top, or even close to the potential range in the short to medium term&#8221; with the maximum options Vega for March and June above this price point.
Verbitskii stated that probability &#8220;tends to zero&#8221; and noted a personal forecast of the beginning of February for Bitcoin to reach this price point once again. 
"The expected influence of Tramp's presidency would likely drive Bitcoin over its former all-time high,&#8221; he added.
While experts agree that the recent downturn is influenced by the Federal Reserve&#8217;s hawkish stance and the <a href="https://www.benzinga.com/markets/cryptocurrency/25/01/42890745/us-government-granted-permission-to-liquidate-65-billion-in-bitcoin-seized-from-silk-road-case-report">DOJ&#8217;s Bitcoin sales</a>, many believe the long-term outlook remains bullish.
The inauguration of Donald Trump is expected to introduce additional variables and while there may be short-term turbulence, there is a consensus view that the market will ultimately rebound, potentially reaching new highs in the coming months. 
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/01/42899528/3-bearish-factors-that-could-drag-bitcoin-below-90000">3 Bearish Factors That Could Drag Bitcoin Below $90,000</a></li>
</ul>
Image created using artificial intelligence with Midjourney.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

EXCLUSIVE: Bitcoin Tumbling, But Bull Market Top Isn't In Yet, Experts Say

Restaurant Development
During the fourth quarter 2024, there were 25 new system-wide restaurant openings consisting of 23 company-owned restaurants and 2 franchise-owned restaurants. Select new restaurant openings experienced minor delays, which resulted in fewer fourth quarter operating weeks than previously planned.
During 2024, there were 50 system-wide new restaurant openings (43 company-owned and 7 franchise-owned), and two closures.
At December 29, 2024, First Watch had 572 system-wide restaurants, consisting of 489 company-owned restaurants and 83 franchise-owned restaurants across 29 states.

FWRG

First Watch Restaurant Reports Q4 25 New Restaurant Openings

B of A Securities analyst Noah Hungness downgrades Chord Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRD#NASDAQ">CHRD</a>) from Buy to Neutral and lowers the price target from $208 to $138.

Downgrades

CHRD

B of A Securities Downgrades Chord Energy to Neutral, Lowers Price Target to $138

Contracts

Oshkosh Secures $29.9M Contract Modification To Integrate Next-generation Autonomous Technology Into ROGUE-Fires With Deliveries Beginning In 2025

Aquestive Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AQST#NASDAQ">AQST</a>) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today provided an update on recent business developments and outlined key objectives for 2025.
"In 2024, we significantly advanced the Company and delivered on our key milestones. Our achievements last year have positioned the Company for continued success in 2025," said Dan Barber, President and Chief Executive Officer of Aquestive. "We believe our long-term growth strategy remains compelling with the potential approval and launches of Anaphylm, Libervant (patients 6+), and AQST-108 in the U.S. and around the world. Our focus in 2025 is on 1) preparing for the potential approval and launch of Anaphylm for the treatment of severe allergies, including anaphylaxis, in the U.S. as early as the first quarter of 2026, 2) actively pursuing our ex-U.S. development strategy for Anaphylm, 3) successfully conducting our Phase 2a clinical trial in alopecia areata for AQST-108, 4) continuing to expand our sales of Libervant&#xAE; (diazepam) Buccal Film for patients between two to five years of age, and (5) continuing to shift our current revenue base from legacy products to Libervant and other growth opportunities. This is truly an exciting time at Aquestive."

AQST

Aquestive Therapeutics Outlines 2025 Goals, Including Anaphylm Launch and AQST-108 Phase 2a Trial

D. Boral Capital analyst Jason Kolbert maintains CytoSorbents (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTSO#NASDAQ">CTSO</a>) with a Buy and maintains $10 price target.

CTSO

D. Boral Capital Maintains Buy on CytoSorbents, Maintains $10 Price Target

B of A Securities analyst Noah Hungness downgrades EOG Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EOG#NYSE">EOG</a>) from Buy to Neutral and lowers the price target from $151 to $144.

B of A Securities Downgrades EOG Resources to Neutral, Lowers Price Target to $144

The acquisition strengthens Bausch + Lomb's expanding clinical-stage pipeline.
Whitecap Biosciences was founded in 2015 to develop novel therapies for ophthalmic diseases with a focus on glaucoma, GA and other serious eye diseases.
&nbsp;

BLCO

Bausch + Lomb Affiliate Acquires Whitecap Biosciences, LLC; No Terms Disclosed

The Edge founder Jim Osman is reportedly campaigning for a full breakup of planemaker Boeing Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>). 
What Happened: Osman <a href="https://www.barrons.com/amp/articles/boeing-stock-benefit-breakup-specialist-94f5dc7b">told</a> Barron&#8217;s that he would like to see Boeing split into its three main divisions of commercial aerospace, defense, and services. 
According to Osman, shareholders are not going to wait forever for the company to start creating value. "It's time for&nbsp;Boeing&nbsp;'s&nbsp;management to wake up and start creating value. The clock is ticking on [management's] job security and shareholders aren't waiting forever," he said. 
According to LinkedIn, Osman&#8217;s The Edge specializes in identifying &#8220;hidden corporate value.&#8221; According to him, there is a 100% upside in Boeing stock if the company undergoes a breakup. 
Why It Matters: Boeing has been faced with one crisis after the other over the past few years, starting in late 2018 when a Boeing aircraft went down in the sea off the coast of Indonesia. 
In January 2024, a door panel flew off an Alaska Airlines plane manufactured by Boeing, creating further concerns. The Covid-19 pandemic in the middle did not help the company&#8217;s financial constraints. 
Boeing stock is down 47% over the past five years and by 14% over the past year, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>. 
Boeing&#8217;s new CEO Kelly Ortberg, who took the reigns of the company in August, has since undertaken stringent measures <a href="https://www.benzinga.com/tech/24/12/42699274/boeing-engineers-leave-struggling-planemaker-for-space-companies-report">including layoffs </a>and <a href="https://www.benzinga.com/markets/equities/24/10/41606547/boeing-eyes-20-7-billion-windfall-as-stock-offering-expands-details">raising capital to salvage its financials.</a> There have been no announcements to date regarding a possible breakup. 
In the third quarter between July and September, Boeing reported a core operating loss of $5,989 million, up from $1,089 million in the corresponding quarter a year ago. The Global Services segment was its sole profitable segment in the quarter, creating earnings from operations of $834 million. 
The Commercial Airplanes and the Defense, Space, and Security segments incurred losses from operations of $4,021 million and $2,384 million, respectively, in the quarter.
Boeing has a consensus price target of $197.89, derived from the assessments of 22 analysts, <a href="https://www.benzinga.com/quote/BA/analyst-ratings">tracked by Benzinga.</a> Barclays, Deutsche Bank, and JP Morgan released their most recent ratings on Jan. 6, Jan. 2, and Nov. 25, respectively, collectively suggesting a 19.64% upside potential.
<figure class="wp-block-image size-large"><a href="https://www.benzinga.com/quote/BA/analyst-ratings"><img decoding="async" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/13074636/Screenshot-2025-01-13-at-6.16.25%E2%80%AFPM-1024x384.png" alt="" class="wp-image-730367" /></a></figure>
Check out more of Benzinga's Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/space/25/01/42868860/starships-raptor-engine-needs-few-final-touches-before-reaching-perfection-says-spacex-ceo-elon-musk" target="_blank" rel="noreferrer noopener">Starship's Raptor Engine Needs ‘Few Final Touches' Before Reaching Perfection, Says SpaceX CEO Elon Musk</a></li>
</ul>
Image via Shutterstock

Equities

Markets

Boeing Stock Wiped Out 47% Of Investor Wealth Over The Last 5 Years Amid Multiple Issues — Now, This Expert Suggests A Breakup Could Benefit The Airplane Maker

Oliveda International: High Risk, High Reward

Press Releases

Oliveda International, Inc. Announces 3,000% Quarterly Revenue Growth for Olive Tree People Subsidiary and Its Waterless Beauty Movement

Oliveda International, Inc. Announces Olive Tree People Subsidiary Surpassing $2 Million Daily Sales 18 Months After Launching in the U.S.

Oliveda International, Inc. Announces Plans to Provide over 1,000 Water Wells in Africa

Oliveda International, Inc. Subsidiary Olive Tree People Announces Global Expansion

Oliveda International, Inc. (OLVI) Announces 2,500% Growth of Olive Tree People Subsidiary

Small Cap

A New Era in Skincare: OLIVE TREE PEOPLE Launches OLIVE ROSE, the World's First Waterless Hydroxytyrosol Skin Tint

Health Care

Oliveda International, Inc. (OLVI) Announces Olive Tree People Subsidiary Surpassing $3.7 Million in Daily Sales 21 Months After Launching in the U.S.

Oliveda International, Inc. (OLVI) Subsidiary Olive Tree People Leads Waterless Beauty Movement with Global Growth into Canada, the UK, throughout Europe and Worldwide

Oliveda International, Inc. (OLVI) Announces 1,650% Fourth Quarter Growth for Olive Tree People Inc. Subsidiary

Oliveda Intl

Mobiquity Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOBQ#NASDAQ">MOBQ</a>) announced that it has appointed Don Walker &ldquo;Trey&rdquo; Barrett, III to the role of Chief Operations and Strategy Officer, effective January 4, 2022.
"Mobiquity&rsquo;s strategy has never been more compelling, and our team will be highly focused on&nbsp; winning customers and growing the business," said Barrett, "I am incredibly excited to join the Mobiquity team and energized to help lead the Company in its next phase of innovation, growth and operational excellence."
Mr. Barrett most recently served as Chief Operating Officer for NYSE-listed Inuvo Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INUV#NYSE">INUV</a>). As COO of Inuvo, Mr. Barrett was responsible for the global operations of IT, Sales, Product, Engineering, Marketing and Accounts Services. During Mr. Barrett&rsquo;s tenure at Inuvo, he managed the company&rsquo;s operations during significant revenue growth ($20 million a year to over $61 million) and personnel development and led several M&amp;A integrations.
Mr. Barrett has over 35 years of data-driven direct marketing and company leadership experience that has been focused on developing, marketing, and delivering technology-driven business services and solutions, providing outstanding client service, driving profitable revenue growth and creating a world-class work environment for associates.
"The new role of Chief Operations and Strategy Officer reflects our commitment to significant growth and continuous improvement for our businesses. Trey is a seasoned and trusted leader who consistently delivers results. He is uniquely qualified to drive strategic prioritization and accountability within Mobiquity, with a laser-focus on operational excellence," said. Dean Julia, CEO of Mobiquity Technologies.
Mobiquity Technology's Platform-as-a-Service (PaaS) company for data and advertising has them joining the ranks with SurgePays (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SURG#NASDAQ">SURG</a>), Oliveda International Inc. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/OLVI#OTC">OLVI</a>), CMG Holdings Group, Inc. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CMGO#OTC">CMGO</a>), Mastermind, Inc. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MMND#OTC">MMND</a>) and Adaptive Medias (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ADTM#OTC">ADTM</a>).
The preceding post was written and/or published as a collaboration between Benzinga&rsquo;s in-house sponsored content team and a financial partner of Benzinga. Although the piece is not and should not be construed as editorial content, the sponsored content team works to ensure that any and all information contained within is true and accurate to the best of their knowledge and research. The content was purely for informational purposes only and not intended to be investing advice.

Comments

Oliveda Intl

News

Latest news for Oliveda Intl (OTC:OLVI) Stock

Thursday, January 06, 2022

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga